Literature DB >> 25862705

Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia.

Cristina Bugarin1, Jolanda Sarno1, Chiara Palmi1, Angela Maria Savino1, Geertruy te Kronnie2, Michael Dworzak3, Angela Shumich3, Barbara Buldini2, Oscar Maglia1, Simona Sala1, Ilaria Bronzini2, Jean-Pierre Bourquin4, Ester Mejstrikova5, Ondrej Hrusak5, Drorit Luria6, Giuseppe Basso2, Shai Izraeli6, Andrea Biondi7, Giovanni Cazzaniga1, Giuseppe Gaipa1.   

Abstract

Entities:  

Keywords:  CRLF2; JAK/STAT; childhood ALL; flow cytometry

Mesh：

Substances：

Year:  2015        PMID： 25862705      PMCID： PMC4450636          DOI： 10.3324/haematol.2014.114447

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Thymic stromal lymphopoietin: a cytokine that promotes the development of IgM+ B cells in vitro and signals via a novel mechanism.

Authors:  S D Levin; R M Koelling; S L Friend; D E Isaksen; S F Ziegler; R M Perlmutter; A G Farr
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

2.  Requirement for stat5 in thymic stromal lymphopoietin-mediated signal transduction.

Authors:  D E Isaksen; H Baumann; P A Trobridge; A G Farr; S D Levin; S F Ziegler
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

3.  Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.

Authors:  Gunnar Cario; Martin Zimmermann; Renja Romey; Stefan Gesk; Inga Vater; Jochen Harbott; André Schrauder; Anja Moericke; Shai Izraeli; Takashi Akasaka; Martin J S Dyer; Reiner Siebert; Martin Schrappe; Martin Stanulla
Journal:  Blood       Date:  2010-04-08       Impact factor: 22.113

4.  Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.

Authors:  Sarah K Tasian; Michelle Y Doral; Michael J Borowitz; Brent L Wood; I-Ming Chen; Richard C Harvey; Julie M Gastier-Foster; Cheryl L Willman; Stephen P Hunger; Charles G Mullighan; Mignon L Loh
Journal:  Blood       Date:  2012-06-08       Impact factor: 22.113

5.  Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.

Authors:  Kathryn G Roberts; Ryan D Morin; Jinghui Zhang; Martin Hirst; Yongjun Zhao; Xiaoping Su; Shann-Ching Chen; Debbie Payne-Turner; Michelle L Churchman; Richard C Harvey; Xiang Chen; Corynn Kasap; Chunhua Yan; Jared Becksfort; Richard P Finney; David T Teachey; Shannon L Maude; Kane Tse; Richard Moore; Steven Jones; Karen Mungall; Inanc Birol; Michael N Edmonson; Ying Hu; Kenneth E Buetow; I-Ming Chen; William L Carroll; Lei Wei; Jing Ma; Maria Kleppe; Ross L Levine; Guillermo Garcia-Manero; Eric Larsen; Neil P Shah; Meenakshi Devidas; Gregory Reaman; Malcolm Smith; Steven W Paugh; William E Evans; Stephan A Grupp; Sima Jeha; Ching-Hon Pui; Daniela S Gerhard; James R Downing; Cheryl L Willman; Mignon Loh; Stephen P Hunger; Marco A Marra; Charles G Mullighan
Journal:  Cancer Cell       Date:  2012-08-14       Impact factor: 31.743

6.  Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia.

Authors:  C Palmi; E Vendramini; D Silvestri; G Longinotti; D Frison; G Cario; C Shochat; M Stanulla; V Rossi; A M Di Meglio; T Villa; E Giarin; G Fazio; A Leszl; M Schrappe; G Basso; A Biondi; S Izraeli; V Conter; M G Valsecchi; G Cazzaniga; G Te Kronnie
Journal:  Leukemia       Date:  2012-04-09       Impact factor: 11.528

7.  Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.

Authors:  Richard C Harvey; Charles G Mullighan; I-Ming Chen; Walker Wharton; Fady M Mikhail; Andrew J Carroll; Huining Kang; Wei Liu; Kevin K Dobbin; Malcolm A Smith; William L Carroll; Meenakshi Devidas; W Paul Bowman; Bruce M Camitta; Gregory H Reaman; Stephen P Hunger; James R Downing; Cheryl L Willman
Journal:  Blood       Date:  2010-02-04       Impact factor: 22.113

8.  Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; J Racquel Collins-Underwood; Letha A A Phillips; Michael G Loudin; Wei Liu; Jinghui Zhang; Jing Ma; Elaine Coustan-Smith; Richard C Harvey; Cheryl L Willman; Fady M Mikhail; Julia Meyer; Andrew J Carroll; Richard T Williams; Jinjun Cheng; Nyla A Heerema; Giuseppe Basso; Andrea Pession; Ching-Hon Pui; Susana C Raimondi; Stephen P Hunger; James R Downing; William L Carroll; Karen R Rabin
Journal:  Nat Genet       Date:  2009-10-18       Impact factor: 38.330

9.  Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.

Authors:  Lisa J Russell; Melania Capasso; Inga Vater; Takashi Akasaka; Olivier A Bernard; Maria Jose Calasanz; Thiruppavaii Chandrasekaran; Elise Chapiro; Stephan Gesk; Mike Griffiths; David S Guttery; Claudia Haferlach; Lana Harder; Olaf Heidenreich; Julie Irving; Lyndal Kearney; Florence Nguyen-Khac; Lee Machado; Lynne Minto; Aneela Majid; Anthony V Moorman; Heather Morrison; Vikki Rand; Jonathan C Strefford; Claire Schwab; Holger Tönnies; Martin J S Dyer; Reiner Siebert; Christine J Harrison
Journal:  Blood       Date:  2009-07-29       Impact factor: 22.113

10.  Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.

Authors:  Arian van der Veer; Esmé Waanders; Rob Pieters; Marieke E Willemse; Simon V Van Reijmersdal; Lisa J Russell; Christine J Harrison; William E Evans; Vincent H J van der Velden; Peter M Hoogerbrugge; Frank Van Leeuwen; Gabriele Escherich; Martin A Horstmann; Leila Mohammadi Khankahdani; Dimitris Rizopoulos; Hester A De Groot-Kruseman; Edwin Sonneveld; Roland P Kuiper; Monique L Den Boer
Journal:  Blood       Date:  2013-08-23       Impact factor: 22.113
View more
  10 in total

Review 1.  Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia.

Authors:  Richard C Harvey; Sarah K Tasian
Journal:  Blood Adv       Date:  2020-01-14

2.  The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.

Authors:  A M Savino; J Sarno; L Trentin; M Vieri; G Fazio; M Bardini; C Bugarin; G Fossati; K L Davis; G Gaipa; S Izraeli; L H Meyer; G P Nolan; A Biondi; G Te Kronnie; C Palmi; G Cazzaniga
Journal:  Leukemia       Date:  2017-03-23       Impact factor: 11.528

3.  Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.

Authors:  Harpreet Virk; Sonia Rana; Praveen Sharma; Parveen Lata Bose; Diksha Dev Yadav; Man Updesh Singh Sachdeva; Neelam Varma; Amita Trehan; Deepesh Lad; Alka Rani Khadwal; Pankaj Malhotra; Sreejesh Sreedharanunni
Journal:  Ann Hematol       Date:  2021-06-22       Impact factor: 3.673

Review 4.  Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.

Authors:  Sarah D Cramer; Peter D Aplan; Scott K Durum
Journal:  Blood       Date:  2016-06-06       Impact factor: 22.113

5.  SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia.

Authors:  Jolanda Sarno; Angela M Savino; Chiara Buracchi; Chiara Palmi; Stefania Pinto; Cristina Bugarin; Astraea Jager; Silvia Bresolin; Ruth C Barber; Daniela Silvestri; Shai Israeli; Martin J S Dyer; Giovanni Cazzaniga; Garry P Nolan; Andrea Biondi; Kara L Davis; Giuseppe Gaipa
Journal:  Oncotarget       Date:  2018-05-01

Review 6.  Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia.

Authors:  Agata Pastorczak; Krzysztof Domka; Klaudyna Fidyt; Martyna Poprzeczko; Malgorzata Firczuk
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

Review 7.  JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies.

Authors:  Charlotte Ej Downes; Barbara J McClure; Daniel P McDougal; Susan L Heatley; John B Bruning; Daniel Thomas; David T Yeung; Deborah L White
Journal:  Front Cell Dev Biol       Date:  2022-07-12

8.  CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia.

Authors:  Chiara Palmi; Angela M Savino; Daniela Silvestri; Ilaria Bronzini; Gunnar Cario; Maddalena Paganin; Barbara Buldini; Marta Galbiati; Martina U Muckenthaler; Cristina Bugarin; Pamela Della Mina; Stefan Nagel; Elena Barisone; Fiorina Casale; Franco Locatelli; Luca Lo Nigro; Concetta Micalizzi; Rosanna Parasole; Andrea Pession; Maria C Putti; Nicola Santoro; Anna M Testi; Ottavio Ziino; Andreas E Kulozik; Martin Zimmermann; Martin Schrappe; Antonello Villa; Giuseppe Gaipa; Giuseppe Basso; Andrea Biondi; Maria G Valsecchi; Martin Stanulla; Valentino Conter; Geertruy Te Kronnie; Giovanni Cazzaniga
Journal:  Oncotarget       Date:  2016-09-13

9.  Surface expression of Cytokine Receptor-Like Factor 2 increases risk of relapse in pediatric acute lymphoblastic leukemia patients harboring IKZF1 deletions.

Authors:  Agata Pastorczak; Lukasz Sedek; Marcin Braun; Joanna Madzio; Alicja Sonsala; Magdalena Twardoch; Wojciech Fendler; Karin Nebral; Joanna Taha; Marta Bielska; Patryk Gorniak; Magdalena Romiszewska; Michal Matysiak; Katarzyna Derwich; Monika Lejman; Jerzy Kowalczyk; Wanda Badowska; Maciej Niedzwiecki; Bernarda Kazanowska; Katarzyna Muszynska-Roslan; Grazyna Sobol-Milejska; Grazyna Karolczyk; Andrzej Koltan; Tomasz Ociepa; Tomasz Szczepanski; Wojciech Młynarski
Journal:  Oncotarget       Date:  2018-05-25

Review 10.  New biological and genetic classification and therapeutically relevant categories in childhood B-cell precursor acute lymphoblastic leukemia.

Authors:  Jan Starý; Jan Zuna; Marketa Zaliova
Journal:  F1000Res       Date:  2018-09-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.